

FEDERICO NICHETTI

Fondazione IRCCS
Istituto Nazionale dei Tumori
Prof. Filippo De Braud
Direttore SC Medicina Oncologica 1

PROFESSIONAL EXPERIENCES

GERMAN CANCER RESEARCH CENTER (DKFZ)

Research fellow in Bioinformatics

Computational Oncology, Molecular Diagnostics Program,

Supervisor: Daniel Huebschmann, Dr. rer. nat. Dr. med.; Stefan Fröhling, Prof. Dr. med.

HEIDELBERG, GERMANY

Aug 2020 – ongoing

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Intern Student - Resident - Medical Oncologist

Medical Oncology Department, Supervisor: Filippo De Braud, Professor, MD.

MILAN, ITALY

Sep 2013 – ongoing

ST. VINCENT'S UNIVERSITY HOSPITAL

Visiting Student

Medical Oncology Department, Supervisors: Giuseppe Gullo, MD; John Crown, Professor, MD.

DUBLIN, IRELAND

Oct 2014 – Nov 2014

EDUCATION

UNIVERSITÀ DEGLI STUDI DI MILANO

Scuola di Specializzazione in Oncologia Medica | Residency School in Medical Oncology

Final score: 70/70 cum laude.

Final Thesis: *Integrated Metabolic Subtyping of Biliary Tract Cancers.*

Supervisors: Filippo De Braud, Professor, MD; Daniel Huebschmann, Dr. rer. nat. Dr. med., CASM

MILAN, ITALY

Nov 2016 – Oct 2021

ADVANCED TOPICS IN BIOSTATISTICS

Organized by the German Cancer Research Center (DKFZ) Division of Biostatistics

HEIDELBERG, GERMANY

Oct 2020 – Mar 2021

UNIVERSITÀ DEGLI STUDI DI MILANO

Laurea Magistrale in Medicina e Chirurgia | M.D. Degree • Final score: 110/110 cum laude.

Final Thesis: *Thrombophilic gene mutations and thromboembolic events in metastatic colorectal cancer patients.*

Supervisors: Filippo Pietrantonio, MD; Paolo Foa, Professor, MD

MILAN, ITALY

Sep 2009 – Jul 2015

LICEO CLASSICO "A. RACCHETTI"

Classical studies high school Diploma • Final score: 100/100

CREMA, ITALY

Sep 2004 – Jul 2009

NORTH COTE COLLEGE SCHOOL TERM

Spent the first term living in a local family for a high school exchange program.

AUCKLAND, NEW ZEALAND

Jul 2007 – Oct 2007

PROFESSIONAL AFFILIATIONS

- A.S.C.O. - AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MEMBER ID: 6923918
- A.A.C.R. - AMERICAN ASSOCIATION FOR CANCER RESEARCH, MEMBER ID: 1206117
- E.S.M.O. - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, MEMBER ID: 351842
- E.A.C.R. - EUROPEAN ASSOCIATION FOR CANCER RESEARCH, MEMBER ID: EACR26050
- A.I.O.M. - ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA
- O.M.Ce.O.Mi. - ORDINE PROVINCIALE DEI MEDICI CHIRURGHI E DEGLI ODONTOIATRI DI MILANO, N° MATR.44351
- I.B.S. - INTERNATIONAL BIOMETRIC SOCIETY - ITALIAN REGION

AWARDS AND OTHER PROJECTS

PREMIO GIOVANI PER ATTIVITÀ DI RICERCA IN AMBITO ONCOLOGICO

Convegno Nazionale AIOM Giovani "2018: News in Oncology"

Awarded for 'Best Abstract'.

Title: *"Impact of EVERolimus-induced precocious modifications of systemic METabolism on the prognosis of postmenopausal women with advanced hormone receptor-positive HER2 negative breast cancer: preliminary monocentric data from the ongoing retrospective, multicenter italian EVERMET study".*

PERUGIA, ITALY

Jul 2018

PREMIO DI STUDIO A.A. 2016/2017 "LUCIANA COSTA"

Fondazione Costa di Ivrea (TO)

Awarded with a prize of €2,000 in favor of master graduates in Medicine and Surgery or specialists in Medical Oncology at a University in Lombardy (Italy) who have discussed a thesis in Oncology from January 2015 to December 2016.

MILAN, ITALY

Nov 2017

THE CHRISTIE, SCHOOL OF ONCOLOGY

International Cancer Careers Conference 2015

First prize awards for 'Best Oral Presentation' and 'Best Abstract'.

MANCHESTER, UNITED KINGDOM

Sep 2015

Title: *Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients.*

PREMIO DI STUDIO A.A. 2016/2017 "LUCIANA COSTA"

Fondazione Costa di Ivrea (TO)

Awarded with a prize of €2,000 in favor of master graduates in Medicine and Surgery or specialists in Medical Oncology at a University in Lombardy (Italy) who have discussed a thesis in Oncology from January 2015 to December 2016.

MILAN, ITALY

Nov 2017

LANGUAGES:

Italian: mother tongue.

German: einfacher Benutzer – Goethe Institut level B1.

English: Proficient User – TOEFL iBT® Test, score 106/120 (Aug 2011) – CEFR level C2.

PUBLICATIONS

- Inno A, Fanetti G, Bartolomeo MD, Gori S, Maggi C, Cirillo M, Iacovelli R, **Nichetti F**, Martinetti A, de Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. *World J Clin Cases*. 2014 Dec 2.
- Falvella S, Cremolini C, Miceli R, **Nichetti F**, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, Loupakis F, Pietrantonio F. Variant Alleles in Factor V, Prothrombin, Plasminogen Activator Inhibitor-1, Methylenetetrahydrofolate Reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. *Pharmacogenomics J*. 2016 Mar 22.
- Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Barattelli C, Salvatore L, Marmorino F, Borelli B, **Nichetti F**, Bironzo P, Sonetto C, Di Bartolomeo M, De Braud F, Loupakis F, Falcone A, Di Maio M. Surrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysis. *Cancer Res Treat*. 2016 Nov 15.
- **Nichetti F**, Lobefaro R, Pagani F, Randon G, Corti F, de Braud F, Celio L, Platania M. "Systemic strategy at the patient's service": a congress report on supportive care in oncology. *Tumori*. 2017 Jul 27.
- Cavalieri S, Morelli D, Martinetti A, Galli G, **Nichetti F**, de Braud F, Platania M. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. *Int J Biol Markers*. 2017 Sep 25.
- Cremolini C, Pietrantonio F, Tomasello G, Dadduzio G, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, **Nichetti F**, Ziapirri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*. 2017 Aug 2.
- **Nichetti F**, Morano F, Fabbri A, De Braud F, Di Bartolomeo M. Bilateral Parotid Gland Metastases from Gastric Signet-Ring Cell Carcinoma. *Tumori*. 2017 Nov 22.
- Vernieri C, **Nichetti F**, Raimondi A, Pusceddu S, Platania M, Berrino F and de Braud F. Diet and supplements in cancer prevention and treatment: clinical evidences and future perspectives. *Crit Rev Oncol Hematol*. 2018 Mar.
- Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; **NEPscore Working Group**. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Jun.
- **Nichetti F***, Marra A*, Corti F, Guidi A, Raimondi A, Prinzi N, de Braud F, Pusceddu S. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. *Target Oncol*. 2018 Apr 14.
- Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassinetti GL, Mosconi S, **Nichetti F**, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*. 2018 May 8.
- Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, **Nichetti F**, Martinetti A, Battaglia L, Perrone F, Pruner G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Ann Oncol*. 2018 May 31.
- Raimondi A, **Nichetti F**, Peverelli G, Di Bartolomeo M, de Braud F, Pietrantonio F. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. *Pharmacogenomics*. 2018 Jul 25.
- Femia D, Prinzi N, Anichini A, Mortarini R, **Nichetti F**, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. *Target Oncol*. 2018 Aug 2.
- Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, **Nichetti F**, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. *Clin Colorectal Cancer*. 2018 Nov 23.

- Corti F*, **Nichetti F***, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. *Cancer Treat Rev.* 2018 Nov 9.
- Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, **Nichetti F**, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol.* 2018 Dec 11.
- **Nichetti F**, Falvella FS, Miceli R, Cheli S, Gaetano R, Fucà G, Infante G, Martinetti A, Antoniotti C, Falcone A, Di Bartolomeo M, Cremolini C, de Braud F, Pietrantonio F. Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? *Pharmacogenomics J.* 2019 Feb 4.
- Galli G, Cavalieri S, Di Guardo L, Cimminiello C, **Nichetti F**, Corti F, Garcia MA, Pappalardi B, Fallai C, de Braud F, Platania M, Del Vecchio M. Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. *Oncol Res Treat.* 2019 Mar 5.
- Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, **Nichetti F**, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C. Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. *Clin Colorectal Cancer.* 2019 Mar 7.
- Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, **Nichetti F**, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Cancers (Basel).* 2019 Apr 5.
- Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, **Nichetti F**, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattermi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in T advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer.* 2019 Apr 1.
- Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, **Nichetti F**, Russo GL, Giacomelli L, Mazzaferro V, Bartolomeo MD, Seregini E, Braud F, Pusceddu S. Somatostatin analogs in association with peptide receptor radionuclide therapy in advanced well-differentiated NETs. *Future Oncol.* 2019 Aug 19.
- **Nichetti F**, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Is There an Interplay Between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. *Cancers.* 2019 Dic 25.
- Vernieri C, Prisciandaro M, **Nichetti F**, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers.* 2020 Mar 6.
- Vernieri C, Corti F, **Nichetti F**, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. *Breast Cancer Res.* 2020 Apr 6.
- Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, **Nichetti F**, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A; HYPERCAN Investigators. Thrombin generation predicts for early recurrence in breast cancer patients. *J Thromb Haemost.* 2020 May 12.
- Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, **Nichetti F**, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clin Colorectal Cancer.* 2020 May 23.
- **Nichetti F**, Lo Russo G, Prelaj A, Provenzano L, de Braud F, Cabiddu M, Garassino MC, Petrelli F. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? *Thromb Res.* 2020 Jun 24.
- Niger M, Prisciandaro M, Antista M, Monica MAT, Cattaneo L, Prinzi N, Manglaviti S, **Nichetti F**, Brambilla M, Torchio M, Corti F, Pusceddu S, Coppa J, Mazzaferro V, de Braud F, Di Bartolomeo M. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World J Gastrointest Oncol.* 2020 Aug 15.
- **Nichetti F**, Bini M, Ambrosini M, Ottini A, Rametta A, Leporati R, Polastri D, Pircher C, Dotti K, Ferrari L, de Braud F. COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. *ESMO Open.* 2020 Nov 5.
- Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, **Nichetti F**, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. *Cancers (Basel).* 2020 Nov 10.
- Procopio G, **Nichetti F**, Verzoni E. Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. *Lancet Oncol.* 2020 Oct 23.
- Zattarin E, Ligorio F, **Nichetti F**, Bianchi G, Capri G, de Braud F. Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview. *Tumori.* 2020 Dec 9.

- Lobefaro R, Zattarin E, **Nichetti F**, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. *Ther Adv Med Oncol*. 2020 Dec 7.
- Rovesti G, Leone F, Brandi G, Fornaro L, Scartozzi M, Niger M, Yoo C, Caputo F, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Vivaldi C, Cho H, Lai E, Fenocchio E, **Nichetti F**, Pella N, De Lorenzo S, Di Maio M, Vasile E, de Braud F, Jeong JH, Aprile G, Orsi G, Cascinu S, Casadei-Gardini A. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. *J Gastrointest Cancer*. 2021 Feb 5.
- Vernieri C*, **Nichetti F***, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). *Clin Cancer Res*, 2021 Mar 30.
- Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, **Nichetti F**, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *Eur J Cancer*, 2021 Apr 4.
- **Nichetti F**, Ligorio F, Montelatici G, Porcu L, Zattarin E, Provenzano L, Franza A, Lalli L, de Braud F, Platania M. Risk assessment of thromboembolic events in hospitalized cancer patients. *Sci Rep*, 2021 Sep 14.

*contributed equally.

12/11/2021

